THE COST-EFFECTIVENESS AND BUDGET IMPACT OF EARLY RITUXIMAB USE IN ASYMPTOMATIC FOLLICULAR LYMPHOMA (FL) IN THE US

被引：0
|
作者：
Shelbaya, A. [1 ,2 ]
Kowal, S. [3 ]
Wehler, E. [4 ]
Ferrufino, C. [5 ]
Al Taie, A. [1 ]
Nava-Parada, P. [1 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Columbia Univ, Mailman Sch Publ Hlth, Heliopolis, Egypt
[3] IQVIA, Shelby Township, MI USA
[4] IQVIA, Plymouth Meeting, PA USA
[5] IQVIA, Falls Church, VA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN130
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of rituximab in follicular lymphoma
    Johnston, Karissa M.
    Bolbocean, Corneliu
    Connors, Joseph
    Peacock, Stuart
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 569 - 577
  • [2] Cost-effectiveness of rituximab maintenance therapy for patients with follicular lymphoma: The Spanish perspective
    Gomez Codina, J.
    Provencio, M.
    Rueda, A.
    Capote, F.
    Carbonell, F.
    Conde, E.
    Fernandez Ranada, J.
    Giraldo, P.
    Rios, E.
    Varela, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
    Spencer, Scott J.
    Guzauskas, Gregory F.
    FeLizzi, Federico
    Launonen, Aino
    Dawson, Keith
    Veenstra, David L.
    Masaquel, Anthony
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (05): : 615 - 624
  • [4] Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL).
    Leppae, Sirpa
    Linna, Miika
    Nyman, Heidi
    Taimela, Eeva
    [J]. BLOOD, 2006, 108 (11) : 952A - 952A
  • [5] Frontline Rituximab Monotherapy Induction Versus a Watch and Wait Approach For Asymptomatic Advanced Stage Follicular Lymphoma: A Cost-Effectiveness Analysis
    Prica, Anca
    Chan, Kelvin K. W.
    Cheung, Matthew C.
    [J]. BLOOD, 2013, 122 (21)
  • [6] COST-EFFECTIVENESS OF RITUXIMAB-BASED CHEMOTHERAPY COMBINATIONS FOR THE INTIAL THERAPY OF FOLLICULAR LYMPHOMA
    Shah, G.
    Winn, A.
    Kumar, A.
    Lin, P.
    Parsons, S.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A221 - A221
  • [7] THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
    Zhao, M. M.
    Xiang, Y.
    Juying, W.
    Jia, S. H.
    Chen, B. B.
    Fan, C. S.
    [J]. VALUE IN HEALTH, 2019, 22 : S455 - S455
  • [8] Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis
    Prica, Anca
    Chan, Kelvin
    Cheung, Matthew
    [J]. CANCER, 2015, 121 (15) : 2637 - 2645
  • [9] Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission
    Hayslip, John W.
    Simpson, Kit N.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (03): : 166 - 170
  • [10] Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study
    Blommestein, Hedwig M.
    Issa, Djamila E.
    Pompen, Marjolein
    Revil, Cedric
    Hoogendoorn, Mels
    Joosten, Peter
    Zweegman, Sonja
    Huijgens, Peter C.
    Uyl-de Groot, Carin A.
    [J]. BLOOD, 2012, 120 (21)
12345